

Content highlights

Publication date
April 2025

Geography
China

Primary research
Qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 75 medical oncologists in China

Epidemiology
Diagnosed incidence of breast cancer in China, with urban and rural breakup. Clinically and market-relevant drug-treatable populations

Forecast
10-year, annualized, drug-level sales and patient share of key breast cancer therapies through 2034, based on primary and secondary market research to formulate bottom-up assumptions

Drug treatments
Coverage of key current and late-phase emerging therapies

Custom drug modeler
Integrated tool to input customized forecast assumptions (e.g., launch date, price)

Breast Cancer

China In-Depth

The breast cancer therapy market in mainland China is one of the most dynamic in the oncology sector. Several new and emerging therapies are expected to gain approval for specific subpopulations, representing significant advances in breast cancer treatment. Although these approvals will boost sales during the 2024-2034 forecast period, intense competition among agents in key treatable populations will limit the potential of individual therapies. In addition, although price erosion is anticipated to be less severe with biosimilars than with small-molecule drugs, the extensive use of trastuzumab and pertuzumab biosimilars, especially in the early-stage and first-line metastatic settings, will dampen overall sales. In this report, we assess how clinical and nonclinical factors—price dynamics, inclusion in the NRDL—will influence the launch and uptake of new breast cancer therapies in China. Understanding the impact of these intersecting factors will be key to the success of current and future players.

Questions answered

- How large is China's drug-treatable breast cancer population, and how will drug-treatment rates change during the forecast period?
- Which are the most commercially relevant drugs in China's breast cancer market, and why?
- What are the key unmet needs in the management of breast cancer in China?
- What are the key drivers and constraints in this market, and how will the market evolve over the forecast period?

Product description

China In-Depth offers comprehensive market intelligence with world-class epidemiology, insight into the China-specific market access landscape, current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

- Optimize your long-term disease and development strategy in China.
- Quantify market potential for your pipeline assets and those of your competitors.
- Understand current treatment paradigms, the complex access and reimbursement environment, and the current and future therapeutic landscape.
- Gauge the commercial outlook and impact of key market events.

Learn more about Clarivate's full suite of breast cancer solutions:

healthcare.support@clarivate.com | clarivate.com

© 2025 Clarivate. Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.